Faculty:
Baharak Moshiree, MD, MSc, FACG, AGAF
Professor of Medicine
Director of University of North Carolina, Department of Medicine
Atrium Health Gastroenterology and Hepatology
Charlotte, NC
Satish Rao, MD, PhD, FRCP (LON), FACG, AGAF
J. Harold Harrison, MD, Distinguished University Chair in Gastroenterology
Professor of Medicine
Augusta University Medical Center
Augusta, GA
Target Audience:
This CME monograph is targeted at primary care physicians and allied health care providers.
Goal Statement:
The goal of this monograph will focus on emerging treatment updates, reviewing current treatment guidelines, and advances in the management of irritable bowel syndrome (IBS).
Educational Objectives:
After completing this activity, participants should be better able to:
- Recognize symptoms of IBS and chronic constipation and describe strategies for diagnosing these conditions
- Identify patients with alarm symptoms who require further diagnostic investigation
- Describe the evidence regarding the efficacy and safety of conventional and newer therapies for IBS and chronic constipation
- Understand mechanisms and specific symptoms targeted by the newer IBS therapies
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and the Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Purdue University College of Pharmacy designates this journal supplement for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP (American Academy of Family Physicians) Accreditation:
The AAFP has reviewed IBS Prime Journal Supplement and deemed it acceptable for up to 2.00 Medical Journals, Self-Study AAFP Prescribed credit. Term of Approval is from 01/01/2021 to 12/31/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement:
Nursing Accreditation Statement:
Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This program has been approved for 1.0 contact hour.
Disclosure Statement:
All faculty, staff and reviewers involved
in the planning, review or presentation of
continuing education activities provided
by Purdue University College of Pharmacy
are required to disclose to the audience any
relevant commercial financial affiliations
related to the content of the presentation
or enduring material. Full disclosure of all
commercial relationships must be made in
writing to the audience prior to the activity.
All additional planning committee members, staff and reviewers of The GI Health Foundation and Purdue University College of Pharmacy have no relationships to disclose.
Disclosures:
Satish Rao discloses that he is on advisory boards for In Control Medical, Ironwood Pharmaceuticals, Neurogut, Inc., Progenity, Quin-Tron, Takeda Pharmaceuticals, Valeant Pharmaceuticals, and Vibrant; and that he has received research grants from Progenity, Valeant Pharmaceuticals, and Vibrant.
Baharak Moshiree discloses that he is on advisory boards for Salix and Takeda; that he has received research grants from Allergan, Progenity, Salix, Takeda, and Urovant; and that he participates in speakers bureaus for QOL Medical, Salix, and Takeda. Julianne Messick, PharmD (medical writer) discloses she has no conflicts of interest.
This program is supported by educational grants from Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc.
Provided by:
Accredited by:
